News
SGHT
5.14
+4.68%
0.23
Weekly Report: what happened at SGHT last week (0720-0724)?
Weekly Report · 8h ago
Sight Sciences to report Q2 financial results after market close
PUBT · 4d ago
Sight Sciences to Report Second Quarter 2026 Financial Results on August 5, 2026
Barchart · 5d ago
Weekly Report: what happened at SGHT last week (0713-0717)?
Weekly Report · 07/20 10:27
Weekly Report: what happened at SGHT last week (0706-0710)?
Weekly Report · 07/13 10:29
Have Insiders Sold Sight Sciences Shares Recently?
Simply Wall St · 07/09 10:13
Sight Sciences Is Maintained at Neutral by Citigroup
Dow Jones · 07/08 15:52
Sight Sciences Price Target Raised to $6.00/Share From $5.15 by Citigroup
Dow Jones · 07/08 15:52
Citigroup Maintains Neutral on Sight Sciences, Raises Price Target to $6
Benzinga · 07/08 15:42
Sight Sciences price target raised to $6 from $5.15 at Citi
TipRanks · 07/08 10:40
Citi Keeps Their Hold Rating on Sight Sciences (SGHT)
TipRanks · 07/08 09:45
Top Executives Quietly Unload Sight Sciences Shares in a Significant Insider Shake-Up
TipRanks · 07/07 02:04
Weekly Report: what happened at SGHT last week (0629-0703)?
Weekly Report · 07/06 10:33
Weekly Report: what happened at SGHT last week (0622-0626)?
Weekly Report · 06/29 10:28
Weekly Report: what happened at SGHT last week (0615-0619)?
Weekly Report · 06/22 10:39
Weekly Report: what happened at SGHT last week (0608-0612)?
Weekly Report · 06/15 10:39
Insider Confidence Surges as Sight Sciences Director Makes Bold Stock Move
TipRanks · 06/12 02:10
Sight Sciences director, 10% owner Staffan Encrantz buys 14,100 shares worth $68,793.90
PUBT · 06/11 20:44
Discover 3 Promising Penny Stocks With Market Caps Over $20M
Simply Wall St · 06/09 11:05
More
Webull provides a variety of real-time SGHT stock news. You can receive the latest news about Sight Sciences, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About SGHT
Sight Sciences, Inc. is an eyecare technology company. The Company is focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The Company operates through two segments: Surgical Glaucoma and Dry Eye. The product portfolio for the Surgical Glaucoma segment features the OMNI Surgical System, which is an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma, and the SION Surgical Instrument is a bladeless, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The product portfolio for the Dry Eye segment consists of the TearCare System (TearCare) for ophthalmologists and optometrists. TearCare is used by adult patients with evaporative dry eye disease due to meibomian gland disease (MGD), enabling clearance of gland obstructions by physicians to address the cause of dry eye disease.